Osteoprotegerin is a Significant Prognostic Factor for Overall Survival in Patients with Primary Systemic Amyloidosis Independent of the Mayo Staging

Kastritis, Eftathios; Gavriatopoulos, M.; Eleutherakis‐Papaiakovou, Evangelos; Kanellias, Nikolaos; Ρούσσου, Μαρία; Pamboucas, Constantinos; Toumanidis, Savvas; Terpos, Evangelos

doi:10.1016/j.clml.2015.07.483

Cited by 1 publication

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The bone marrow microenvironment is crucial for the survival of the clone and drug resistance, but this aspect of the biology of AL amyloidosis has not been extensively studied. Cytokine profiles (including those with inflammatory, pro‐angiogenic or antiogenic properties, osteoclast and osteoblast regulators) are distinct from what has been described in MM (Kastritis et al , , ). Some of these cytokines may have prognostic significance, which may also be due to their expression by other tissues that are affected by amyloid toxicity.…”

Section: The Plasma Cell Clone In Al Amyloidosismentioning

confidence: 87%

Recent advances in the management of AL Amyloidosis

Kastritis

2015

Br J Haematol

View full text Add to dashboard Cite

Immunoglobulin light chain (AL) amyloidosis, the most common of the systemic amyloidosis, is characterized by the deposition of amyloid fibrils that derive from the aggregation of misfolded monoclonal immunoglobulin light chains. Amyloid fibrils disrupt tissue architecture and the pre-fibril oligomers are directly toxic to myocardiac cells, causing cardiac dysfunction. The lethal consequences of AL amyloidosis are due to the toxic product and not due to the malignant behaviour of the plasma cell clone; however, the characteristics of this clone are associated with long-term prognosis. Early and accurate diagnosis is the key to effective management, but is challenging. Modern chemotherapy options (including autologous transplantation, bortezomib, lenalidomide) have improved the outcomes of patients at low or intermediate risk, but the prognosis of patients with severe cardiac dysfunction is still poor. Therapies targeting amyloid deposits and the amyloidogenic process are under investigation and offer promise for better future treatments.

show abstract

Section: The Plasma Cell Clone In Al Amyloidosismentioning

confidence: 87%

Recent advances in the management of AL Amyloidosis

Kastritis

2015

Br J Haematol

View full text Add to dashboard Cite

show abstract

Osteoprotegerin is a Significant Prognostic Factor for Overall Survival in Patients with Primary Systemic Amyloidosis Independent of the Mayo Staging

Cited by 1 publication

References 7 publications

Recent advances in the management of AL Amyloidosis

Recent advances in the management of AL Amyloidosis

Contact Info

Product

Resources

About